Header Logo

Connection

Robin Jones to Humans

Back to Details
This is a "connection" page, showing publications Robin Jones has written about Humans.
Robin Jones
Connection Strength
3.304
Humans
  1. Management of Vascular Sarcoma. Surg Oncol Clin N Am. 2022 07; 31(3):485-510.
    View in: PubMed
    Score: 0.046
  2. Efficacy and Safety of TRC105 Plus Pazopanib vs Pazopanib Alone for Treatment of Patients With Advanced Angiosarcoma: A Randomized Clinical Trial. JAMA Oncol. 2022 05 01; 8(5):740-747.
    View in: PubMed
    Score: 0.046
  3. KIT Exon 9-Mutated Gastrointestinal Stromal Tumours: Biology and Treatment. Chemotherapy. 2022; 67(2):81-90.
    View in: PubMed
    Score: 0.045
  4. The evolving management of epithelioid sarcoma. Eur J Cancer Care (Engl). 2021 Nov; 30(6):e13489.
    View in: PubMed
    Score: 0.043
  5. Cardiac safety of trabectedin monotherapy or in combination with pegylated liposomal doxorubicin in patients with sarcomas and ovarian cancer. Cancer Med. 2021 06; 10(11):3565-3574.
    View in: PubMed
    Score: 0.043
  6. Current Reality of Treating Advanced Soft Tissue Sarcoma as Illustrated by Case Studies. Oncology. 2021; 99 Suppl 1:8-16.
    View in: PubMed
    Score: 0.043
  7. Prospective Evaluation of Doxorubicin Cardiotoxicity in Patients with Advanced Soft-tissue Sarcoma Treated in the ANNOUNCE Phase III Randomized Trial. Clin Cancer Res. 2021 07 15; 27(14):3861-3866.
    View in: PubMed
    Score: 0.042
  8. Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial. Eur J Cancer. 2021 03; 145:132-142.
    View in: PubMed
    Score: 0.042
  9. Future Directions in the Treatment of Osteosarcoma. Cells. 2021 01 15; 10(1).
    View in: PubMed
    Score: 0.042
  10. Efficacy of Gemcitabine-based Chemotherapy in Clear Cell Sarcoma of Soft Tissue. Anticancer Res. 2020 Dec; 40(12):7003-7007.
    View in: PubMed
    Score: 0.042
  11. Circulating Tumor Cells and Biomarker Modulation with Olaratumab Monotherapy Followed by Olaratumab plus Doxorubicin: Phase Ib Study in Patients with Soft-Tissue Sarcoma. Mol Cancer Ther. 2021 01; 20(1):132-141.
    View in: PubMed
    Score: 0.041
  12. Sirolimus for patients with progressive epithelioid hemangioendothelioma. Cancer. 2021 02 15; 127(4):504-506.
    View in: PubMed
    Score: 0.041
  13. Gynecological Sarcomas: Molecular Characteristics, Behavior, and Histology-Driven Therapy. Int J Surg Pathol. 2021 Feb; 29(1):4-20.
    View in: PubMed
    Score: 0.041
  14. Evaluation of the use and efficacy of (neo)adjuvant chemotherapy in angiosarcoma: a multicentre study. ESMO Open. 2020 08; 5(4).
    View in: PubMed
    Score: 0.041
  15. Telemedicine During the COVID-19 Pandemic: Impact on Care for Rare Cancers. JCO Glob Oncol. 2020 07; 6:1046-1051.
    View in: PubMed
    Score: 0.040
  16. Avapritinib in the treatment of PDGFRA exon 18 mutated gastrointestinal stromal tumors. Future Oncol. 2020 Aug; 16(22):1639-1646.
    View in: PubMed
    Score: 0.040
  17. Revolutions in treatment options in gastrointestinal stromal tumours (GISTs): the latest updates Curr Treat Options Oncol. 2020 05 27; 21(7):55.
    View in: PubMed
    Score: 0.040
  18. Low-grade Fibromyxoid Sarcoma: Treatment Outcomes and Efficacy of Chemotherapy. In Vivo. 2020 Jan-Feb; 34(1):239-245.
    View in: PubMed
    Score: 0.039
  19. Adult soft tissue myoepithelial carcinoma: treatment outcomes and efficacy of chemotherapy. Med Oncol. 2019 Dec 27; 37(2):13.
    View in: PubMed
    Score: 0.039
  20. Ewing-like sarcomas: New molecular diagnoses in need of optimized treatment approaches. Indian J Med Res. 2019 12; 150(6):521-523.
    View in: PubMed
    Score: 0.039
  21. Negative phase III trials announce the need for biomarkers in sarcoma. Eur J Cancer. 2019 12; 123:81-82.
    View in: PubMed
    Score: 0.039
  22. Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours. Eur J Cancer. 2019 10; 120:132-139.
    View in: PubMed
    Score: 0.038
  23. Sarcomas and old age: few options for such a large patient population. Future Oncol. 2019 Sep; 15(26s):11-15.
    View in: PubMed
    Score: 0.038
  24. Safety and efficacy of trabectedin when administered in the inpatient versus outpatient setting: Clinical considerations for outpatient administration of trabectedin. Cancer. 2019 Dec 15; 125(24):4435-4441.
    View in: PubMed
    Score: 0.038
  25. The Role of Local Therapy in Multi-focal Epithelioid Haemangioendothelioma. Anticancer Res. 2019 Sep; 39(9):4891-4896.
    View in: PubMed
    Score: 0.038
  26. Subgroup analysis of older patients treated within the randomized phase 3 doxorubicin versus doxorubicin plus evofosfamide (SARC021) trial. J Geriatr Oncol. 2020 04; 11(3):463-469.
    View in: PubMed
    Score: 0.037
  27. A phase 1 and randomized controlled phase 2 trial of the safety and efficacy of the combination of gemcitabine and docetaxel with ontuxizumab (MORAb-004) in metastatic soft-tissue sarcomas. Cancer. 2019 07 15; 125(14):2445-2454.
    View in: PubMed
    Score: 0.037
  28. Gemcitabine Re-challenge in Metastatic Soft Tissue Sarcomas: A Therapeutic Option for Selected Patients. Anticancer Res. 2019 Jan; 39(1):347-351.
    View in: PubMed
    Score: 0.036
  29. Preserving quality of life as a key treatment goal in advanced soft tissue sarcomas. Expert Rev Anticancer Ther. 2018 12; 18(12):1241-1248.
    View in: PubMed
    Score: 0.036
  30. Trends in Modern Phase 1 Oncology Trials. N Engl J Med. 2018 09 20; 379(12):1188-9.
    View in: PubMed
    Score: 0.036
  31. Clinical Characteristics and efficacy of chemotherapy in sclerosing epithelioid fibrosarcoma. Med Oncol. 2018 Sep 05; 35(11):138.
    View in: PubMed
    Score: 0.036
  32. Synovial Sarcoma of the Thyroid Gland, Diagnostic Pitfalls and Clinical Management. Anticancer Res. 2018 Sep; 38(9):5275-5282.
    View in: PubMed
    Score: 0.036
  33. Poor treatment outcomes with palliative gemcitabine and docetaxel chemotherapy in advanced and metastatic synovial sarcoma. Med Oncol. 2018 Aug 20; 35(10):131.
    View in: PubMed
    Score: 0.035
  34. Quality of life and patients' expectations in soft tissue sarcoma. Future Oncol. 2018 May; 14(10s):51-62.
    View in: PubMed
    Score: 0.035
  35. The current landscape of early drug development for patients with sarcoma in the immunotherapy era. Future Oncol. 2018 May; 14(12):1197-1211.
    View in: PubMed
    Score: 0.035
  36. Clear Cell Sarcoma-like Tumor of the Gastrointestinal Tract: Clinical Outcome and Pathologic Features of a Molecularly Characterized Tertiary Center Case Series. Anticancer Res. 2018 03; 38(3):1479-1483.
    View in: PubMed
    Score: 0.034
  37. Olaratumab in soft tissue sarcoma - Current status and future perspectives. Eur J Cancer. 2018 03; 92:33-39.
    View in: PubMed
    Score: 0.034
  38. Successful Ifosfamide Rechallenge in Soft-Tissue Sarcoma. Am J Clin Oncol. 2018 02; 41(2):147-151.
    View in: PubMed
    Score: 0.034
  39. Sarcoma: Does histotype-tailored neoadjuvant therapy improve outcomes? Nat Rev Clin Oncol. 2017 10; 14(10):589-590.
    View in: PubMed
    Score: 0.033
  40. Olaratumab for the treatment of soft-tissue sarcoma. Future Oncol. 2017 Oct; 13(24):2151-2157.
    View in: PubMed
    Score: 0.033
  41. Treatment of retroperitoneal sarcoma: current standards and new developments. Curr Opin Oncol. 2017 07; 29(4):260-267.
    View in: PubMed
    Score: 0.033
  42. Eribulin in advanced liposarcoma and leiomyosarcoma. Expert Rev Anticancer Ther. 2017 08; 17(8):717-723.
    View in: PubMed
    Score: 0.033
  43. Neoadjuvant chemotherapy in localised soft-tissue sarcomas: where do we go from here? Lancet Oncol. 2017 06; 18(6):706-707.
    View in: PubMed
    Score: 0.033
  44. Q-TWiST: What really matters to the cancer patient? Cancer. 2017 06 15; 123(12):2200-2202.
    View in: PubMed
    Score: 0.032
  45. Phase III Soft Tissue Sarcoma Trials: Success or Failure? Curr Treat Options Oncol. 2017 03; 18(3):19.
    View in: PubMed
    Score: 0.032
  46. Treatment of soft tissue sarcoma: a focus on earlier stages. Future Oncol. 2017 Jan; 13(1s):13-21.
    View in: PubMed
    Score: 0.032
  47. Dear John Hunter. BMJ. 2016 12 14; 355:i6515.
    View in: PubMed
    Score: 0.032
  48. Understanding sarcomas and other rare tumors: an interview with Robin L Jones. Future Oncol. 2017 Feb; 13(5):391-394.
    View in: PubMed
    Score: 0.032
  49. Molecular subtypes of gastrointestinal stromal tumors and their prognostic and therapeutic implications. Future Oncol. 2017 Jan; 13(1):93-107.
    View in: PubMed
    Score: 0.031
  50. Promising novel therapeutic approaches in the management of gastrointestinal stromal tumors. Future Oncol. 2017 Jan; 13(2):185-194.
    View in: PubMed
    Score: 0.031
  51. Drug repositioning in sarcomas and other rare tumors. EBioMedicine. 2016 Apr; 6:4-5.
    View in: PubMed
    Score: 0.030
  52. Histology-Driven Therapy: The Importance of Diagnostic Accuracy in Guiding Systemic Therapy of Soft Tissue Tumors. Int J Surg Pathol. 2016 Feb; 24(1):5-15.
    View in: PubMed
    Score: 0.029
  53. A phase I open-label trial evaluating the cardiovascular safety of regorafenib in patients with advanced cancer. Cancer Chemother Pharmacol. 2015 Oct; 76(4):777-84.
    View in: PubMed
    Score: 0.029
  54. Redefining the standard of care in metastatic leiomyosarcoma. Lancet Oncol. 2015 Apr; 16(4):360-2.
    View in: PubMed
    Score: 0.028
  55. Cardio-oncology: a special focus issue from Future Oncology. Future Oncol. 2015; 11(14):1993-4.
    View in: PubMed
    Score: 0.028
  56. Current and advancing systemic treatment options for soft tissue sarcomas. Expert Opin Pharmacother. 2015; 16(13):2023-37.
    View in: PubMed
    Score: 0.028
  57. Analysis of clinical prognostic factors for adult patients with head and neck sarcomas. Otolaryngol Head Neck Surg. 2014 Dec; 151(6):976-83.
    View in: PubMed
    Score: 0.027
  58. Success is not final and failure is not fatal. J Clin Oncol. 2014 Oct 20; 32(30):3449-50.
    View in: PubMed
    Score: 0.027
  59. Phase I study of intermittent oral dosing of the insulin-like growth factor-1 and insulin receptors inhibitor OSI-906 in patients with advanced solid tumors. Clin Cancer Res. 2015 Feb 15; 21(4):693-700.
    View in: PubMed
    Score: 0.027
  60. A Phase II multicenter, open-label, clinical and pharmokinetic trial of PM00104 in patients with advanced Ewing Family of Tumors. Invest New Drugs. 2014 Feb; 32(1):171-7.
    View in: PubMed
    Score: 0.025
  61. New drugs and clinical trial design in advanced sarcoma: have we made any progress? Future Oncol. 2013 Oct; 9(10):1409-11.
    View in: PubMed
    Score: 0.025
  62. Clinical benefit of trabectedin in uterine adenosarcoma. Med Oncol. 2013 Jun; 30(2):501.
    View in: PubMed
    Score: 0.024
  63. Role of palliative chemotherapy in advanced epithelioid sarcoma. Am J Clin Oncol. 2012 Aug; 35(4):351-7.
    View in: PubMed
    Score: 0.023
  64. Chemotherapy in clear cell sarcoma. Med Oncol. 2011 Sep; 28(3):859-63.
    View in: PubMed
    Score: 0.022
  65. Nuclear NF-?B/p65 expression and response to neoadjuvant chemotherapy in breast cancer. J Clin Pathol. 2011 Feb; 64(2):130-5.
    View in: PubMed
    Score: 0.021
  66. Clinical benefit of early phase clinical trial participation for advanced sarcoma patients. Cancer Chemother Pharmacol. 2011 Aug; 68(2):423-9.
    View in: PubMed
    Score: 0.021
  67. Relationship between oestrogen receptor status and proliferation in predicting response and long-term outcome to neoadjuvant chemotherapy for breast cancer. Breast Cancer Res Treat. 2010 Jan; 119(2):315-23.
    View in: PubMed
    Score: 0.018
  68. Utility of dexrazoxane for the reduction of anthracycline-induced cardiotoxicity. Expert Rev Cardiovasc Ther. 2008 Nov; 6(10):1311-7.
    View in: PubMed
    Score: 0.018
  69. The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat. 2009 Jul; 116(1):53-68.
    View in: PubMed
    Score: 0.018
  70. Anthracycline cardiotoxicity. Expert Opin Drug Saf. 2006 Nov; 5(6):791-809.
    View in: PubMed
    Score: 0.016
  71. Neoadjuvant treatment for early-stage breast cancer: opportunities to assess tumour response. Lancet Oncol. 2006 Oct; 7(10):869-74.
    View in: PubMed
    Score: 0.016
  72. Cardiac and cardiovascular toxicity of nonanthracycline anticancer drugs. Expert Rev Anticancer Ther. 2006 Sep; 6(9):1249-69.
    View in: PubMed
    Score: 0.015
  73. Differential sensitivity of liposarcoma subtypes to chemotherapy. Eur J Cancer. 2005 Dec; 41(18):2853-60.
    View in: PubMed
    Score: 0.015
  74. The development and application of imatinib. Expert Opin Drug Saf. 2005 Mar; 4(2):183-91.
    View in: PubMed
    Score: 0.014
  75. Use of endomyocardial biopsy to assess anthracycline-induced cardiotoxicity. Lancet Oncol. 2005 Feb; 6(2):67.
    View in: PubMed
    Score: 0.014
  76. Clinical and pathological absence of cardiotoxicity after liposomal doxorubicin. Lancet Oncol. 2004 Sep; 5(9):575-7.
    View in: PubMed
    Score: 0.013
  77. Clinical and molecular prognostic factors in patients with metastatic colorectal cancer treated with 5-fluorouracil-based chemotherapy. Clin Colorectal Cancer. 2003 Feb; 2(4):235-8.
    View in: PubMed
    Score: 0.012
  78. Management of Locally Recurrent Retroperitoneal Sarcoma in the Adult: An Updated Consensus Approach from the Transatlantic Australasian Retroperitoneal Sarcoma Working Group. Ann Surg Oncol. 2022 Nov; 29(12):7335-7348.
    View in: PubMed
    Score: 0.012
  79. Chemotherapy in patients with localized angiosarcoma of any site: A retrospective european study. Eur J Cancer. 2022 08; 171:183-192.
    View in: PubMed
    Score: 0.012
  80. A Phase 1/2 Trial Combining Avelumab and Trabectedin for Advanced Liposarcoma and Leiomyosarcoma. Clin Cancer Res. 2022 06 01; 28(11):2306-2312.
    View in: PubMed
    Score: 0.012
  81. Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study. Clin Cancer Res. 2022 04 14; 28(8):1672-1679.
    View in: PubMed
    Score: 0.011
  82. Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial. J Clin Oncol. 2022 08 01; 40(22):2479-2490.
    View in: PubMed
    Score: 0.011
  83. Risk factors for the development of local recurrence in extremity soft-tissue sarcoma. Expert Rev Anticancer Ther. 2022 Jan; 22(1):83-95.
    View in: PubMed
    Score: 0.011
  84. Oncological Outcome After Diagnostic Biopsies in Gastrointestinal Stromal Tumors: A Retrospective Cohort Study. Ann Surg. 2021 12 01; 274(6):e1093-e1098.
    View in: PubMed
    Score: 0.011
  85. Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: The CAPTURE study. Nat Cancer. 2021 12; 2:1321-1337.
    View in: PubMed
    Score: 0.011
  86. Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study. Nat Cancer. 2021 12; 2(12):1321-1337.
    View in: PubMed
    Score: 0.011
  87. Treatments and Outcomes in Oligometastatic Soft Tissue Soft Sarcoma - A Single Centre Retrospective Analysis. Anticancer Res. 2021 Oct; 41(10):5089-5096.
    View in: PubMed
    Score: 0.011
  88. Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous KIT/PDGFRA Mutations in the Phase III INVICTUS Study. Clin Cancer Res. 2021 12 01; 27(23):6333-6342.
    View in: PubMed
    Score: 0.011
  89. Solitary fibrous tumor: molecular hallmarks and treatment for a rare sarcoma. Future Oncol. 2021 Sep; 17(27):3627-3636.
    View in: PubMed
    Score: 0.011
  90. Clinical Benefit of Ripretinib Dose Escalation After Disease Progression in Advanced Gastrointestinal Stromal Tumor: An Analysis of the INVICTUS Study. Oncologist. 2021 11; 26(11):e2053-e2060.
    View in: PubMed
    Score: 0.011
  91. Ripretinib intrapatient dose escalation after disease progression provides clinically meaningful outcomes in advanced gastrointestinal stromal tumour. Eur J Cancer. 2021 09; 155:236-244.
    View in: PubMed
    Score: 0.011
  92. Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study. J Clin Oncol. 2021 10 01; 39(28):3128-3139.
    View in: PubMed
    Score: 0.011
  93. CD4+ T cell and M2 macrophage infiltration predict dedifferentiated liposarcoma patient outcomes. J Immunother Cancer. 2021 08; 9(8).
    View in: PubMed
    Score: 0.011
  94. Fibroblast Growth Factor Receptor (FGFR) Signaling in GIST and Soft Tissue Sarcomas. Cells. 2021 06 17; 10(6).
    View in: PubMed
    Score: 0.011
  95. Gastrointestinal leiomyosarcoma demonstrate a predilection for distant recurrence and poor response to systemic treatments. Eur J Surg Oncol. 2021 10; 47(10):2595-2601.
    View in: PubMed
    Score: 0.011
  96. Ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities. Cancer. 2021 08 15; 127(16):2934-2942.
    View in: PubMed
    Score: 0.011
  97. Pharmacotherapy for liposarcoma: current and emerging synthetic treatments. Future Oncol. 2021 Jul; 17(20):2659-2670.
    View in: PubMed
    Score: 0.011
  98. Health-related quality of life and pain with selinexor in patients with advanced dedifferentiated liposarcoma. Future Oncol. 2021 Aug; 17(22):2923-2939.
    View in: PubMed
    Score: 0.011
  99. Clinicopathological features and treatment outcome of oesophageal gastrointestinal stromal tumour (GIST): A large, retrospective multicenter European study. Eur J Surg Oncol. 2021 08; 47(8):2173-2181.
    View in: PubMed
    Score: 0.011
  100. Systemic therapies in advanced epithelioid haemangioendothelioma: A retrospective international case series from the World Sarcoma Network and a review of literature. Cancer Med. 2021 04; 10(8):2645-2659.
    View in: PubMed
    Score: 0.011
  101. Avapritinib in Patients With Advanced Gastrointestinal Stromal Tumors Following at Least Three Prior Lines of Therapy. Oncologist. 2021 04; 26(4):e639-e649.
    View in: PubMed
    Score: 0.011
  102. Optimal Avapritinib Treatment Strategies for Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumors. Oncologist. 2021 04; 26(4):e622-e631.
    View in: PubMed
    Score: 0.010
  103. A Phase 1b Study Evaluating the Safety, Tolerability, and Immunogenicity of CMB305, a Lentiviral-Based Prime-Boost Vaccine Regimen, in Patients with Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1. Oncoimmunology. 2020 11 19; 9(1):1847846.
    View in: PubMed
    Score: 0.010
  104. Assessment of Doxorubicin and Pembrolizumab in Patients With Advanced Anthracycline-Naive Sarcoma: A Phase 1/2 Nonrandomized Clinical Trial. JAMA Oncol. 2020 Nov 01; 6(11):1778-1782.
    View in: PubMed
    Score: 0.010
  105. Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study. Lancet Oncol. 2020 11; 21(11):1423-1432.
    View in: PubMed
    Score: 0.010
  106. A Timely Oral Option: Single-Agent Vinorelbine in Desmoid Tumors. Oncologist. 2020 12; 25(12):e2013-e2016.
    View in: PubMed
    Score: 0.010
  107. Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib. J Clin Oncol. 2020 10 01; 38(28):3294-3303.
    View in: PubMed
    Score: 0.010
  108. EWSR1-SMAD3-Positive Fibroblastic Tumor. Int J Surg Pathol. 2021 Apr; 29(2):179-181.
    View in: PubMed
    Score: 0.010
  109. SMARCA4-Deficient Thoracic Sarcoma. Int J Surg Pathol. 2021 Sep; 29(6):640-641.
    View in: PubMed
    Score: 0.010
  110. Superficial CD34-Positive Fibroblastic Tumor. Int J Surg Pathol. 2020 Dec; 28(8):879-881.
    View in: PubMed
    Score: 0.010
  111. Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial. Lancet Oncol. 2020 07; 21(7):935-946.
    View in: PubMed
    Score: 0.010
  112. Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2020 07; 21(7):923-934.
    View in: PubMed
    Score: 0.010
  113. Health-related quality Of Life In patients with advanced Soft TIssue sarcomas treated with Chemotherapy (The HOLISTIC study): protocol for an international observational cohort study. BMJ Open. 2020 06 01; 10(6):e035171.
    View in: PubMed
    Score: 0.010
  114. Metastatic Soft Tissue Sarcomas in Adolescents and Young Adults: A Specialist Center Experience. J Adolesc Young Adult Oncol. 2020 12; 9(6):628-638.
    View in: PubMed
    Score: 0.010
  115. Different approaches to advanced soft tissue sarcomas depending on treatment line, goal of therapy and histological subtype. Expert Rev Anticancer Ther. 2020 04; 20(sup1):15-28.
    View in: PubMed
    Score: 0.010
  116. Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas: The ANNOUNCE Randomized Clinical Trial. JAMA. 2020 04 07; 323(13):1266-1276.
    View in: PubMed
    Score: 0.010
  117. Rib destruction by epithelioid tumour in a young man. J Clin Pathol. 2020 Oct; 73(10):e2.
    View in: PubMed
    Score: 0.010
  118. Primary iliocaval leiomyosarcomas: The path beyond surgery. Eur J Surg Oncol. 2020 05; 46(5):893-897.
    View in: PubMed
    Score: 0.010
  119. Imaging Soft-tissue Sarcomas of the Head and Neck: A Tertiary Soft-tissue Sarcoma Unit Experience. Anticancer Res. 2019 Nov; 39(11):6223-6230.
    View in: PubMed
    Score: 0.010
  120. Systemic treatments in MDM2 positive intimal sarcoma: A multicentre experience with anthracycline, gemcitabine, and pazopanib within the World Sarcoma Network. Cancer. 2020 01 01; 126(1):98-104.
    View in: PubMed
    Score: 0.010
  121. Outcome of Primary Desmoid Tumors at All Anatomic Locations Initially Managed with Active Surveillance. Ann Surg Oncol. 2019 Dec; 26(13):4699-4706.
    View in: PubMed
    Score: 0.010
  122. First-in-Class, First-in-Human Study Evaluating LV305, a Dendritic-Cell Tropic Lentiviral Vector, in Sarcoma and Other Solid Tumors Expressing NY-ESO-1. Clin Cancer Res. 2019 10 01; 25(19):5808-5817.
    View in: PubMed
    Score: 0.009
  123. Role of Chemotherapy, VEGFR Inhibitors, and mTOR Inhibitors in Advanced Perivascular Epithelioid Cell Tumors (PEComas). Clin Cancer Res. 2019 09 01; 25(17):5295-5300.
    View in: PubMed
    Score: 0.009
  124. Probabilistic modeling of personalized drug combinations from integrated chemical screen and molecular data in sarcoma. BMC Cancer. 2019 Jun 17; 19(1):593.
    View in: PubMed
    Score: 0.009
  125. Systemic Interferon-? Increases MHC Class I Expression and T-cell Infiltration in Cold Tumors: Results of a Phase 0 Clinical Trial. Cancer Immunol Res. 2019 08; 7(8):1237-1243.
    View in: PubMed
    Score: 0.009
  126. Pazopanib in patients with advanced intermediate-grade or high-grade liposarcoma. Expert Opin Investig Drugs. 2019 Jun; 28(6):505-511.
    View in: PubMed
    Score: 0.009
  127. Aldoxorubicin in soft tissue sarcomas. Future Oncol. 2019 May; 15(13):1429-1435.
    View in: PubMed
    Score: 0.009
  128. Age-related sarcoma patient experience: results from a national survey in England. BMC Cancer. 2018 Oct 17; 18(1):991.
    View in: PubMed
    Score: 0.009
  129. Anthracycline, Gemcitabine, and Pazopanib in Epithelioid Sarcoma: A Multi-institutional Case Series. JAMA Oncol. 2018 09 01; 4(9):e180219.
    View in: PubMed
    Score: 0.009
  130. Desmoid fibromatosis through the patients' eyes: time to change the focus and organisation of care? Support Care Cancer. 2019 Mar; 27(3):965-980.
    View in: PubMed
    Score: 0.009
  131. Pancreaticoduodenectomy for the Management of Pancreatic or Duodenal Metastases from Primary Sarcoma. Anticancer Res. 2018 Jul; 38(7):4041-4046.
    View in: PubMed
    Score: 0.009
  132. Endometrial Stromal Sarcoma With Hyalinizing Giant Rosettes, Mimicking Low-Grade Fibromyxoid Sarcoma. Int J Surg Pathol. 2018 Sep; 26(6):525-527.
    View in: PubMed
    Score: 0.009
  133. Safety and Efficacy Outcomes of Embolization in Hepatic Sarcomas. AJR Am J Roentgenol. 2018 Jan; 210(1):175-182.
    View in: PubMed
    Score: 0.008
  134. First-in-Human Treatment With a Dendritic Cell-targeting Lentiviral Vector-expressing NY-ESO-1, LV305, Induces Deep, Durable Response in Refractory Metastatic Synovial Sarcoma Patient. J Immunother. 2017 10; 40(8):302-306.
    View in: PubMed
    Score: 0.008
  135. Activity of Eribulin in Patients With Advanced Liposarcoma Demonstrated in a Subgroup Analysis From a Randomized Phase III Study of Eribulin Versus Dacarbazine. J Clin Oncol. 2017 Oct 20; 35(30):3433-3439.
    View in: PubMed
    Score: 0.008
  136. Desmoplastic small round cell tumor: evaluation of reverse transcription-polymerase chain reaction and fluorescence in situ hybridization as ancillary molecular diagnostic techniques. Virchows Arch. 2017 Nov; 471(5):631-640.
    View in: PubMed
    Score: 0.008
  137. The Adequacy of Core Biopsy in the Assessment of Smooth Muscle Neoplasms of Soft Tissues: Implications for Treatment and Prognosis. Am J Surg Pathol. 2017 Jul; 41(7):923-931.
    View in: PubMed
    Score: 0.008
  138. Efficacy and safety of trabectedin or dacarbazine in patients with advanced uterine leiomyosarcoma after failure of anthracycline-based chemotherapy: Subgroup analysis of a phase 3, randomized clinical trial. Gynecol Oncol. 2017 09; 146(3):531-537.
    View in: PubMed
    Score: 0.008
  139. Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2017 08; 18(8):1089-1103.
    View in: PubMed
    Score: 0.008
  140. Pazopanib, a promising option for the treatment of aggressive fibromatosis. Anticancer Drugs. 2017 04; 28(4):421-426.
    View in: PubMed
    Score: 0.008
  141. The spectrum of EWSR1-rearranged neoplasms at a tertiary sarcoma centre; assessing 772 tumour specimens and the value of current ancillary molecular diagnostic modalities. Br J Cancer. 2017 Feb 28; 116(5):669-678.
    View in: PubMed
    Score: 0.008
  142. The Current Landscape of Early Drug Development for Patients With Sarcoma. Am Soc Clin Oncol Educ Book. 2017; 37:807-810.
    View in: PubMed
    Score: 0.008
  143. PICASSO III: A Phase III, Placebo-Controlled Study of Doxorubicin With or Without Palifosfamide in Patients With Metastatic Soft Tissue Sarcoma. J Clin Oncol. 2016 11 10; 34(32):3898-3905.
    View in: PubMed
    Score: 0.008
  144. Dermatofibrosarcoma protuberans: pathology, genetics, and potential therapeutic strategies. Ann Diagn Pathol. 2016 Dec; 25:64-71.
    View in: PubMed
    Score: 0.008
  145. Desmoplastic Small Round Cell Tumor: Pathology, Genetics, and Potential Therapeutic Strategies. Int J Surg Pathol. 2016 Dec; 24(8):672-684.
    View in: PubMed
    Score: 0.008
  146. Endosialin expression in soft tissue sarcoma as a potential marker of undifferentiated mesenchymal cells. Br J Cancer. 2016 08 09; 115(4):473-9.
    View in: PubMed
    Score: 0.008
  147. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial. Lancet. 2016 Jul 30; 388(10043):488-97.
    View in: PubMed
    Score: 0.008
  148. p.(L576P) -KIT mutation in GIST: Favorable prognosis and sensitive to imatinib? Cancer Biol Ther. 2016 05 03; 17(5):543-5.
    View in: PubMed
    Score: 0.007
  149. The Current Status of Solitary Fibrous Tumor: Diagnostic Features, Variants, and Genetics. Int J Surg Pathol. 2016 Jun; 24(4):281-92.
    View in: PubMed
    Score: 0.007
  150. Dedifferentiated Liposarcoma: Updates on Morphology, Genetics, and Therapeutic Strategies. Adv Anat Pathol. 2016 Jan; 23(1):30-40.
    View in: PubMed
    Score: 0.007
  151. Epithelioid Sarcoma: Diagnostic Features and Genetics. Adv Anat Pathol. 2016 Jan; 23(1):41-9.
    View in: PubMed
    Score: 0.007
  152. Adult Pleomorphic Rhabdomyosarcoma: A Multicentre Retrospective Study. Anticancer Res. 2015 Nov; 35(11):6213-7.
    View in: PubMed
    Score: 0.007
  153. Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial. J Clin Oncol. 2016 Mar 10; 34(8):786-93.
    View in: PubMed
    Score: 0.007
  154. Synovial sarcoma diagnosis and management in the era of targeted therapies. Curr Opin Oncol. 2015 Jul; 27(4):316-22.
    View in: PubMed
    Score: 0.007
  155. The maternal early warning criteria: a proposal from the national partnership for maternal safety. Obstet Gynecol. 2014 Oct; 124(4):782-786.
    View in: PubMed
    Score: 0.007
  156. The maternal early warning criteria: a proposal from the national partnership for maternal safety. J Obstet Gynecol Neonatal Nurs. 2014 Nov-Dec; 43(6):771-9.
    View in: PubMed
    Score: 0.007
  157. Inference of tumor evolution during chemotherapy by computational modeling and in situ analysis of genetic and phenotypic cellular diversity. Cell Rep. 2014 Feb 13; 6(3):514-27.
    View in: PubMed
    Score: 0.006
  158. Phase I trial of preoperative chemoradiation plus sorafenib for high-risk extremity soft tissue sarcomas with dynamic contrast-enhanced MRI correlates. Clin Cancer Res. 2013 Dec 15; 19(24):6902-11.
    View in: PubMed
    Score: 0.006
  159. Reducing maternal deaths through state maternal mortality review. J Womens Health (Larchmt). 2012 Sep; 21(9):905-9.
    View in: PubMed
    Score: 0.006
  160. NYESO-1/LAGE-1s and PRAME are targets for antigen specific T cells in chondrosarcoma following treatment with 5-Aza-2-deoxycitabine. PLoS One. 2012; 7(2):e32165.
    View in: PubMed
    Score: 0.006
  161. Conventional anthracycline-based chemotherapy has limited efficacy in solitary fibrous tumour. Acta Oncol. 2012 Apr; 51(4):550-4.
    View in: PubMed
    Score: 0.006
  162. Trabectedin in advanced uterine leiomyosarcomas: a retrospective case series analysis from two reference centers. Gynecol Oncol. 2011 Dec; 123(3):553-6.
    View in: PubMed
    Score: 0.005
  163. Down-regulation of the miRNA master regulators Drosha and Dicer is associated with specific subgroups of breast cancer. Eur J Cancer. 2011 Jan; 47(1):138-50.
    View in: PubMed
    Score: 0.005
  164. Advanced aggressive fibromatosis: Effective palliation with chemotherapy. Acta Oncol. 2011 Apr; 50(3):455-61.
    View in: PubMed
    Score: 0.005
  165. Beyond triple-negative breast cancer: the need to define new subtypes. Expert Rev Anticancer Ther. 2010 Aug; 10(8):1197-213.
    View in: PubMed
    Score: 0.005
  166. PPM1D gene amplification and overexpression in breast cancer: a qRT-PCR and chromogenic in situ hybridization study. Mod Pathol. 2010 Oct; 23(10):1334-45.
    View in: PubMed
    Score: 0.005
  167. Biological rationale and current clinical experience with anti-insulin-like growth factor 1 receptor monoclonal antibodies in treating sarcoma: twenty years from the bench to the bedside. Cancer J. 2010 May-Jun; 16(3):183-94.
    View in: PubMed
    Score: 0.005
  168. Pegylated liposomal doxorubicin, an effective, well-tolerated treatment for refractory aggressive fibromatosis. Eur J Cancer. 2009 Nov; 45(17):2930-4.
    View in: PubMed
    Score: 0.005
  169. Methylated NEUROD1 promoter is a marker for chemosensitivity in breast cancer. Clin Cancer Res. 2008 Jun 01; 14(11):3494-502.
    View in: PubMed
    Score: 0.004
  170. Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients. Breast Cancer Res Treat. 2008 Sep; 111(1):27-44.
    View in: PubMed
    Score: 0.004
  171. Distribution and significance of caveolin 2 expression in normal breast and invasive breast cancer: an immunofluorescence and immunohistochemical analysis. Breast Cancer Res Treat. 2008 Jul; 110(2):245-56.
    View in: PubMed
    Score: 0.004
  172. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol. 2007 Jul; 8(7):595-602.
    View in: PubMed
    Score: 0.004
  173. Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer. Breast Cancer Res Treat. 2007 Dec; 106(2):181-9.
    View in: PubMed
    Score: 0.004
  174. Caveolin 1 is overexpressed and amplified in a subset of basal-like and metaplastic breast carcinomas: a morphologic, ultrastructural, immunohistochemical, and in situ hybridization analysis. Clin Cancer Res. 2007 Jan 01; 13(1):90-101.
    View in: PubMed
    Score: 0.004
  175. MYC amplification in breast cancer: a chromogenic in situ hybridisation study. J Clin Pathol. 2007 Sep; 60(9):1017-23.
    View in: PubMed
    Score: 0.004
  176. Cyclin D1 protein overexpression and CCND1 amplification in breast carcinomas: an immunohistochemical and chromogenic in situ hybridisation analysis. Mod Pathol. 2006 Jul; 19(7):999-1009.
    View in: PubMed
    Score: 0.004
  177. Distribution and significance of nerve growth factor receptor (NGFR/p75NTR) in normal, benign and malignant breast tissue. Mod Pathol. 2006 Feb; 19(2):307-19.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.